Please assess the completion status of the following clinical trial:

Trial Title: A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* A male or female adult between 18 and 50 years of age.~* Written informed consent.~* Free of obvious health problems as established by medical history and history- directed physical examination before entering the study.~* Expected continuous residence in India during study period, without travel outside India~* An efficacious method of contraception must be used during the study for women of childbearing potential.~Exclusion Criteria:~* Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding administration of SA14-14-2 vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within a period of six months before vaccination or at any time during the study period.~* Any confirmed or suspected immunosuppressive or immunodeficient condition.~* A family history of congenital or hereditary immunodeficiency.~* Any antiviral drug therapy within a period of six months before vaccination or at any time during the study period.~* History of significant allergic disease or reactions likely to be exacerbated by any component of the study vaccine, especially allergic disease or reactions to any previous dose of any vaccine.~* History of having received JE vaccine, yellow fever vaccine, tick-borne encephalitis vaccine or experimental flavivirus vaccine.~* History of documented JE infection.~* Detectable anti JE or West Nile neutralizing antibodies in screening tests.~* Acute disease at the time of enrollment. Entry into the study may be deferred until the illness is resolved.~* Acute or chronic, clinically significant, pulmonary, cardiovascular, hepatic, neurological or renal functional abnormality, as determined by history and physical or laboratory examination that is not controlled by drugs.~* Administration of immunoglobulins and/or any blood products within the three months preceding administration of vaccine, or planned administration during the study period.~* Seropositive for HIV, HCV or HbsAg.~* Lactation, pregnancy or intention to get pregnant.~* History of excessive alcohol consumption, drug abuse or significant psychiatric illness.~* Any other condition that in the opinion of the investigator would pose a health risk to the participant or interfere with the evaluation of the vaccine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Vaccine (Type: EXPERIMENTAL): Single dose live attenuated Japanese encephalitis vaccine SA14-14-2

Based on this trial design, predict the completion outcome and termination type (if applicable).